Blood pressure in children with minimal change nephrotic syndrome during oedema and after steroid therapy: the influence of familial essential hypertension.
OBJECTIVE
To verify the variations of blood pressure in children with minimal change nephrotic syndrome and to correlate the blood pressure with familial history of essential hypertension.


METHODS
We measured blood pressure in 49 prepubertal nephrotic children, 17 females and 32 males, in the first week of oedema, and after 4 weeks of ISKDC (International Study of Kidney Disease in Children) standard steroid therapy. The children were divided into two groups: one with and the other without familial history of essential hypertension.


RESULTS
Among all the patients, 65% showed systolic and/or diastolic blood pressure higher than the 90th percentile at the first assessment. Among the children with a familial history of essential hypertension, in the oedematous phase of the nephrotic syndrome, 88% showed blood pressure higher than the 90th percentile and no children showed blood pressure lower than the 75th percentile. After therapy, the percentage of children with blood pressure higher than the 90th percentile was 52%. In the group with a negative familial history, at the onset 53% showed blood pressure over the 90th percentile. After 4 weeks of therapy, the percentage of children with blood pressure higher than the 90th percentile was 34%.


CONCLUSIONS
Our study reveals the influence of familial essential hypertension in the oedematous phase of the nephrotic syndrome in children.
Kontchou
Laure Monthe
LM
Paediatric Nephrology Unit, Department of Paediatrics, University of Florence, Florence, Italy.
Liccioli
Giulia
G
Pela
Ivana
I
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D002648:Child; D002675:Child, Preschool; D004487:Edema / Q000188:drug therapy / Q000503:physiopathology*; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D009402:Nephrosis, Lipoid / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D009404:Nephrotic Syndrome / Q000188:drug therapy / Q000503:physiopathology; D013256:Steroids / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D013256:Steroids